Surface modification of polycarbonate urethane by grafting polyethylene glycol and bivalirudin drug for improving hemocompatibility

As the clinical demand for blood-contacting materials increases, higher requirements are placed on their physicochemical properties, durability and hemocompatibility in vivo. In this work, a multiple functionalized material was developed through a facile modification process. Herein, polycarbonate urethane (PCU) surface was co-modified with polyethylene glycol (PEG) and bivalirudin (BVLD). PCU provides excellent physical and mechanical properties, PEG and BVLD, especially BVLD, enable the surface with outstanding anticoagulant capacity. Specifically, PCU surface was first treated with hexamethylene diisocyanate to introduce active isocyanate groups onto the surface, followed by hydroxy-PEG grafting to improve the hydrophilicity. Finally, BVLD was immobilized on the surface via Michael addition reaction to improve antithrombotic properties. Attenuated total reflection Fourier transforms infrared spectroscopy and UV spectrophotometers were used to confirm the modified surfaces. The hydrophilicity was characterized by static water contact angle measurement, the morphology of the modified surfaces was observed by scanning electron microscopy. Blood compatibility of the modified surfaces was characterized by the hemolysis rate, platelet adhesion assay and cell culture test. The results showed that the BVLD immobilized surface has excellent anticoagulant properties, good fibrin-bound thrombin inhibition, and good resistance against non-specific adhesion of proteins. Hence, the co-modification with PEG and BVLD was proved an encouraging strategy for improving hemocompatibility.     

Incorporation of Lysine-Containing Copolymer with Polyurethane Affording Biomaterial with Specific Adsorption of Plasminogen

A novel biomaterial based on polyurethane (PU) was prepared through physical incorporation of lysine-containing copolymer to improve its hemocompatibility and surface recognition of plasminogen.The lysine-containing copolymer was synthesized via the copolymerization of 2-ethylhexyl methacrylate (EHMA),oligo (ethylene glycol)methyl ether methacrylate (OEGMA) and 6-tert-butoxycarbonyl amino-2-(2-methyl-acryloylamino)-hexanoic acid tert-butyl ester (Lys(P)MA),followed by the deprotection of COOH and ε-NH2 groups on lysine residues in the copolymer.The composition of the copolymer can be adjusted by varying the monomer feed ratio.The three components contribute to improving the compatibility with PU,resistance to nonspecific protein adsorption and specific binding of plasminogen,respectively.The binding capacity towards plasminogen increased with the lysine content in the copolymer.This approach illustrates a simple way for the generation of novel biomaterials with improved hemocompatibility and surface recognition of specific biomolecules.     

Hemocompatible and Bioactive Heparin‐Loaded PCL‐α‐TCP Fibrous Membranes for Bone Tissue Engineering

The combination of bioactive components such as calcium phosphates and fibrous structures are encouraging niche‐mimetic keys for restoring bone defects. However, the importance of hemocompatibility of the membranes is widely ignored. Heparin‐loaded nanocomposite poly(ε‐caprolactone) (PCL)‐α‐tricalcium phosphate (α‐TCP) fibrous membranes are developed to provide bioactive and hemocompatible constructs for bone tissue engineering. Nanocomposite membranes are optimized based on bioactivity, mechanical properties, and cell interaction. Consequently, various concentrations of heparin molecules are loaded within nanocomposite fibrous membranes. In vitro heparin release profiles reveal a sustained release of heparin over the period of 14 days without an initial burst. Moreover, heparin encapsulation enhances mesenchymal stem cell (MSC) attachment and proliferation, depending on the heparin content. It is concluded that the incorporation of heparin within TCP–PCL fibrous membranes provides the most effective cellular interactions through synergistic physical and chemical cues.     

Synthesis and characterization of poly(N‐(2‐mercaptoethyl) acrylamide) microgel for biomedical applications

N‐(2‐mercaptoethyl) acrylamide (MEAM) monomer was synthesized by acrylation of cysteamine and was cross‐linked with ethylene glycol dimethacrylate (EGDMA) via dispersion polymerization forming poly(N‐(2‐mercaptoethyl) acrylamide) (p(MEAM)) microgel. Then, the prepared microgels were tested for potential biomedical use, eg, antioxidant capacity and blood compatibility, cytotoxicity, apoptotic, and necrotic cell death; drug delivery properties were determined. Antioxidant studies of p(MEAM) microgels revealed a super antioxidant capability with total phenol content and trolox equivalent antioxidant capacity as 6.05 ± 1.15 mg/L gallic acid equivalency and 40.96 ± 2.40 mM trolox/g, respectively. Moreover, the blood compatibility of p(MEAM) microgels on fresh blood was resulted in lower than 1.0% hemolysis ratios for all the studied concentration range, and the blood clotting index was determined as 60.66% at 2.0 mg/mL at microgel concentration. The biocompatibility studies employing WST‐1 test on L929 fibroblast cells and DLD‐1 colon cancer cells have shown that p(MEAM) microgel was biocompatible up to 200 μg/mL concentration with the cell viability values of 84.54% and 86.15% on L929 fibroblast and DLD‐1 colon cancer cells, respectively. Using Captopril was used as model drug to test p(MEAM) microgel as drug delivery device for in vitro release studies at different pHs. Release profile of Captopril was found linear up to 5 hours with the released amounts of 9.81, 12.24, and 13.78 mg g^‐1microgel at the pH 1.5, 7.4, and 9.0, respectively.     

高分子纳米材料与血浆蛋白的相互作用

由于纳米材料具有独特的物理和化学性能,使其在许多领域被广泛应用。纳米材料使用的日益增多要求我们仔细评估其难以预料的毒性（细胞毒性、溶血毒性、血液毒性和免疫毒性）和生物学相互作用。到目前为止,已有大量的研究旨在探索纳米材料与人的细胞或蛋白之间的相互作用,也取得了一些重要成果。在临床应用中,有些生物医用纳米材料常通过静脉注射、渗透、溶解和扩散等方式引入到血液组织中。血液是一种高度复杂的组织,主要由红细胞、白细胞、血小板和血浆组成。其中血浆是一个复杂的体液,它包含超过3700种不同的蛋白质。无论采用哪种方式,这些纳米材料将不可避免地会与丰富的血浆蛋白（或其他血液成分）发生某种联系和相互作用。然而,纳米材料和血浆蛋白之间的相互作用,可能在决定纳米材料的毒性方面起到至关重要的作用。目前对纳米材料与血浆蛋白（或其他血液成分）在分子水平会发生怎样的相互作用知之甚少。本文主要综述了典型的三类高分子纳米材料（包括聚阳离子,高分子胶束和药物（基因）/载体复合纳米粒子）与血浆蛋白的相互作用以及研究这些相互作用相关的分析技术的研究进展,这些内容对体内使用的纳米材料的分子设计和血液安全性非常重要。     

The effect of covalent immobilization of sialic acid on the removal of lipopolysaccharide and reactive oxygen species for polyethylene terephthalate

Polyethylene terephthalate (PET) was aminolyzed with 1,6‐diaminohexane (DAH) and then sialic acid (NANA) was immobilized via amidation onto the surface. The surface concentration of NANA was determined by 2‐thiobarbituric acid (TBA) test. The hemocompatibility of the resulting PET fabrics was evaluated based on complete blood count (CBC), coagulating times, and protein adsorption. The ability to remove lipopolysaccharide (LPS) was also determined. In addition, the effect of contacting NANA‐immobilizing PET on the suppression of reactive oxygen species (ROS) production was measured by the chemiluminescence (CL) method. The results show that by immobilizing NANA onto PET, the adhesion of platelet (PLt) was reduced, and oxidative stress was suppressed. The level of LPS was also greatly reduced. Copyright © 2010 John Wiley & Sons, Ltd.     

SiC过渡层制备温度对碳化硅/氟化类金刚石复合薄膜血液相容性的影响

以316L不锈钢为基底,SiC晶体为靶材,Ar为源气体,采用磁控溅射法在不同温度下制备出系列SiC过渡层.然后以高纯石墨作靶,Ar和CHF_3为源气体,在同一工艺条件下再续镀一层氟化类金刚石(F-DLC)薄膜,形成SiC/F-DLC复合薄膜.研究表明,相比于F-DLC薄膜,复合薄膜的附着力显著增加,血液相容性明显改善.通过样品的拉曼和红外光谱分析了不同温度下制备的SiC过渡层以及复合薄膜结构的演变.结果表明,控制SiC过渡层制备温度可以有效调制过渡层中C=C键的比例以及—C—C—不饱和键的密度,复合薄膜中保留较高比例的芳香环式结构以及合适的F/C比是薄膜的血液相容性得以进一步改善的原因,SiC过渡层制备温度控制在500℃左右效果尤为明显.SiC薄膜和F-DLC两种薄膜的界面处形成一定比例的Si—C键和C=C键是导致复合薄膜附着力显著上升的直接原因.适当条件下在316L不锈钢和F-DLC薄膜之间增加SiC过渡层对于增强薄膜的附着力、改善其血液相容性是可行、有效的.     

Graft copolymerization of 2‐methacryloyloxyethyl phosphorylcholine to cellulose in homogeneous media using atom transfer radical polymerization for providing new hemocompatible coating materials

To develop new hemopurification systems based on cellulose membrane, we synthesized a graft copolymer of cellulose with poly(2‐methacryloyloxyethyl phosphorylcholine) (MPC) by a metal‐catalyzed atom transfer radical polymerization process in homogeneous media. First, cellulose was dissolved in a DMAc/LiCl solution system, and it reacted with 2‐bromoisobutyloyl bromide to produce macroinitiator (cell‐BiB). Then, MPC was polymerized to the cellulose backbone in a homogeneous DMSO/methanol mixture solution in the presence of cell‐BiB. Characterization with FT‐IR, NMR, and GPC measurements showed that there obtained a graft copolymer of cellulose backbone and poly(MPC) side chains (cell‐PMPC) with well‐defined structure, indicating a controlled/“living” radical polymerization. The proteins adsorption studies showed that cellulose membranes modified by the as‐prepared cell‐PMPC owns good protein adsorption resistance. © 2008 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 46: 3306–3313, 2008     

Fabrication and characterization of electrospun silk fibroin/TiO2 nanofibrous mats for wound dressings

Silk fibroin (SF) nanofibrous mats were fabricated via electrospinning process. These fibers were blended with TiO₂ nanoparticles (TiO₂ NPs). The influence of TiO₂ NPs on the nanofibrous matrices was investigated by scanning electron microscopy (SEM), transmission electron microscopy, energy‐dispersive X‐ray, and thermogravimetric analysis. The SEM images revealed that the average diameter of the SF/TiO₂ fibers was 385 ± 63 nm when the concentration of SF was up to 10% (w/v). Infrared spectra showed that the β‐sheet structure of the silk fibroin increased after acetone treatment. These SF/TiO₂ nanofibrous mats exhibited higher equilibrium water content and water vapor transmission rate than hydrocolloid dressing. The hemocompatibility and cytocompatibility of SF/TiO₂ nanofibrous mats were evaluated by complete blood count, cell attachment, and the spreading of L929 fibroblasts. These SF/TiO₂ nanofibrous mats exhibited antibacterial activity against Escherichia coli under UV irradiation. Thus, these novel nanocomposite mats may be used for biomedical applications such as wound dressing. Copyright © 2011 John Wiley & Sons, Ltd.